

ANTIGEN PRESENTATION IN THE  
MURINE T-LYMPHOCYTE PROLIFERATIVE RESPONSE  
I. Requirement for Genetic Identity at the Major Histocompatibility  
Complex

BY AKIHIKO YANO, RONALD H. SCHWARTZ, AND WILLIAM E. PAUL

*(From the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases,  
National Institutes of Health, Bethesda, Maryland 20014)*

The importance of the macrophage in the initiation of the immune response to soluble protein antigens has been demonstrated by several investigators (1-5). One of the clearest examples of this is in the guinea pig where the activation of proliferative responses by antigen-primed, thymus-dependent (T) lymphocytes has been shown to depend upon the presence of an auxiliary cell with the characteristics of a macrophage (1, 2). In this system, the critical function of the live macrophages appears to be the presentation of antigen. One of the striking features of this presentation is that it is only efficient when the antigen-presenting cell and the responding cell possess a common allelic form of the guinea pig equivalent of *I* subregions of the major histocompatibility complex (MHC)<sup>1</sup> (1, 2). A similar *I*-region histocompatibility restriction in the activation of T lymphocytes in the mouse has been suggested by studies of the transfer of delayed hypersensitivity (3) and of the priming of helper T lymphocytes (4, 5). In this communication, we directly demonstrate that the activation of proliferative responses of primed mouse peritoneal exudate T lymphocytes by antigen-pulsed spleen cells is histocompatibility restricted. Efficient activation of T lymphocytes from donors primed to 2,4-dinitrophenyl-ovalbumin (DNP-OVA) occurs only when the interacting cells possess a common allelic form of the MHC. In particular, identity at the *I-A* subregion of the MHC, in the face of differences in all other MHC regions, is sufficient for such activation.

**Materials and Methods**

*Animals.* Strains C57BL/10 Sn (B10), B10.A/SgSn (B10.A), B10.D2/nSn (B10.D2), B10.A(5R)/SgSn, B10.BR/SgSn, C57BL/6J (B6), A/HeJ (A), (B6 × A)<sub>F<sub>1</sub></sub>/J hybrids (B6A F<sub>1</sub>), SJL/J, and DBA/2J were obtained from The Jackson Laboratory, Bar Harbor, Maine. A.TL/Sf mice were the progeny of breeding pairs kindly provided by Dr. Donald Shreffler and Dr. Chella David, Washington University, School of Medicine, St. Louis, Mo. Breeding pairs of the B10.A(4R)/Sg strain were kindly provided by Dr. Jack Stimpfling, McLaughlin Research Institute, Great Falls, Mont. BALB/c AnN mice were obtained from the Division of Research Services of the National Institutes

<sup>1</sup> *Abbreviations used in this paper:* DH, delayed-type hypersensitivity; DNP-OVA; 2,4-dinitrophenyl-ovalbumin; FCS, fetal calf serum; MHC, major histocompatibility complex; MLR, mixed lymphocyte reaction; PETLES, peritoneal exudate T-lymphocyte-enriched cells; PFC, plaque-forming cell.

of Health, Bethesda, Md. The (B10 × B10.D2)F<sub>1</sub> hybrids were bred in the Division of Research Services from the parental strains, C57BL/10SnN and B10.D2/nSnN. The (B10 × B10.A)F<sub>1</sub> hybrids were bred in our laboratory from the Jackson parental strains B10 and B10.A. Mice of both sexes were used between 6 and 18 wk of age.

**Antigens.** DNP derivatives of OVA were prepared by reacting 200 mg of twice recrystallized OVA (Mann Research Laboratories, New York) with 10  $\mu$ l of 2,4-dinitrofluorobenzene (Eastman Organic Chemicals Div., Eastman Kodak Co., Rochester, N. Y.) in 5 ml of borate buffer, pH 8.0. The reaction was carried out in the dark for 24 h with constant stirring at room temperature. The supernate was dialyzed against phosphate-buffered saline, pH 7.2 and any precipitated protein removed by centrifugation (2,000 rpm × 10 min). These conjugates contained ~6 mol DNP/mol of protein and are designated DNP<sub>6</sub>OVA.

**Immunization.** DNP<sub>6</sub>OVA was emulsified in complete Freund's adjuvant containing 1 mg/ml of killed *Mycobacterium tuberculosis* (H37Ra) organisms (Difco Laboratories, Detroit, Mich.). Animals were immunized in the hind foot pads with 10  $\mu$ g of antigen in a total of 0.1 ml of emulsion.

**Preparation of Peritoneal Exudate T-Lymphocyte-Enriched Cells (PETLES).** The original and slightly modified procedures for preparing PETLES are described in detail elsewhere (6-8). Briefly, 2-3 wk after immunization, thioglycollate-induced peritoneal exudate cells were harvested and passed over nylon wool columns. The PETLES population eluted from nylon columns contained an average of 5% macrophages, 40% lymphocytes, 53% eosinophils, and <2% B lymphocytes.

**Preparation of Spleen Cells.** Animals were sacrificed by cervical dislocation and the spleens removed aseptically. Spleen cells were flushed out of the capsule using a 21 gauge needle and a 12 ml syringe filled with KHCO<sub>3</sub>-buffered NH<sub>4</sub>Cl (9). The spleen was squeezed gently with a pair of forceps during the flushing to insure maximum release of cells; the erythrocytes were lysed during this procedure. The cell suspension was passed through a wire screen (no. 180 mesh) and washed once with Spinner's modified Eagle's minimal essential medium. The remaining nucleated cells were resuspended in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS; Grand Island Biological Co., Grand Island, N. Y.), 50 U/ml of penicillin G, 250  $\mu$ g/ml of gentamicin (Schering Corp., Kenilworth, N. J.), and  $2 \times 10^{-5}$  M 2-mercaptoethanol. The cells were counted and kept on ice until ready for use. Although other tissues such as nonimmune PETLES and peritoneal exudate cells were used as sources of antigen-presenting cells, spleen cells were utilized in most of the experiments described in this paper because they presented DNP<sub>6</sub>OVA well and were the easiest to prepare.

**Procedure of Brief Antigen Pulsing.** The spleen cells ( $10 \times 10^6$ /ml) were incubated for 60 min at 37°C in RPMI-1640 with 10% FCS, containing appropriate concentrations of DNP<sub>6</sub>OVA and 50  $\mu$ g/ml of mitomycin-C (Sigma Chemical Co., St. Louis, Mo.). The cells were washed five times at 4°C with 1 ml of RPMI-1640 to remove unbound antigen and mitomycin-C, and resuspended in culture medium. These conditions for antigen pulsing were modeled on those previously described for guinea pig peritoneal exudate cells (10, 11). The cells were recounted and adjusted to appropriate concentrations for addition to the cell cultures. In some experiments, DNP<sub>6</sub>OVA-pulsed or non-pulsed spleen cells were killed by incubating at 56°C for 60 min and then cooled to 37°C before mixing with PETLES.

**Cell Cultures.** The procedure for culturing PETLES has been described elsewhere (6, 7). Briefly, 100  $\mu$ l of a 10% FCS-supplemented modified Eagle's-Hanks' medium (modified EHAA) containing  $1-2 \times 10^5$  PETLES were placed in each well of a sterile, U bottom polystyrene, micro-culture plate (Cooke Laboratory Products Div., Dynatech Laboratories Inc., Alexandria, Va.). DNP<sub>6</sub>OVA-pulsed or nonpulsed spleen cell suspensions were added in another 100  $\mu$ l to give a total vol of 200  $\mu$ l. As a control, soluble DNP<sub>6</sub>OVA was added to some wells to give a total vol of 200  $\mu$ l and a final free antigen concentration of 100  $\mu$ g/ml. The cultures were incubated for 3-6 days at 37°C in a humidified atmosphere of 3% CO<sub>2</sub> and 97% air. Approximately 16-18 h before harvesting, the cultures were pulsed with 1  $\mu$ Ci of tritiated-methyl-thymidine (sp act 5 Ci/mmol; Amersham/Searle Corp., Arlington Heights, Ill.). The cells were collected onto glass fiber filter paper strips (no. 934 AH, Whatman Inc., Clifton, N. J.) with a Mash II automated harvester (Microbiological Associates, Rockville, Md.), and washed with distilled water and 95% ethanol. The filter disk containing each sample was then placed in 2 ml of Hydromix scintillation fluid (Yorktown Research Inc., Hackensack, N. J.) and the radioactivity measured in a Beckman liquid scintillation




FIG. 1. Proliferative response (cpm  $\pm$  SEM) of  $1 \times 10^5$  B10.BR PETLES to varying numbers of syngeneic, mitomycin-C-treated spleen cells, pulsed (O—O), or not pulsed (●—●) with 30  $\mu$ g/ml DNP<sub>6</sub>OVA.

counter (Beckman Instruments Inc., Fullerton, Calif.). Determinations were done in triplicate or duplicate and the data are expressed either as mean counts per minute  $\pm$  the standard error of the mean or as the difference between antigen-pulsed and antigen-nonpulsed responses.

## Results

*The Response of PETLES to Antigen Bound to Spleen Cells.* PETLES represent a unique population of primed T lymphocytes in the mouse which is highly enriched for cells that can proliferate in culture in response to the continuous presence of the priming antigen (6–8). In the experiments to be described here, we investigated the parameters of PETLES stimulation when antigen was presented to the T lymphocytes in a cell-bound rather than a soluble form. This was achieved by exposing spleen cells from nonimmunized donors to antigen for 1 h at 37°C and then washing away unbound antigen. At the same time, the spleen cells were inactivated with mitomycin-C so that only the PETLES could incorporate <sup>3</sup>H-thymidine. The response of  $1 \times 10^5$  B10.BR PETLES to DNP<sub>6</sub>OVA bound to varying numbers of B10.BR spleen cells is shown in Fig. 1. The data indicate that a log linear relationship exists between the number of DNP<sub>6</sub>OVA-pulsed spleen cells added and resultant DNA synthesis in the PETLES at a ratio of spleen cells to PETLES of 1:1 or less. The maximum proliferative response was achieved with  $1-2 \times 10^5$  spleen cells. Larger numbers of spleen cells gave no greater response and in fact were often suppressive (data not shown).

The amount of antigen introduced into the system could also be varied by altering the concentration of antigen used to pulse the spleen cells. Fig. 2 shows




FIG. 2. Responses of  $1 \times 10^5$  B10 PETLES to  $1 \times 10^5$  syngeneic spleen cells that were pulsed with varying concentrations of DNP<sub>6</sub>OVA. Results are expressed as cpm  $\pm$  SEM. Each vertical bar represents the upper and lower limits of one SEM.

the response of PETLES to  $1 \times 10^5$  syngeneic B10 spleen cells that had been exposed to various concentrations of DNP<sub>6</sub>OVA. Thymidine incorporation into new DNA increased as the concentration of antigen increased, up to a dose of 100  $\mu$ g/ml. Based on these results, all subsequent experiments employed  $1 \times 10^5$  PETLES mixed with  $1 \times 10^5$  spleen cells pulsed with 30–100  $\mu$ g/ml of DNP<sub>6</sub>OVA.

The activation of primed PETLES by antigen-pulsed spleen cells, under these conditions, appears to reflect an antigen-presentation function of the spleen cells and is not due to simple release of soluble antigen by these cells. This is illustrated both by the data presented below that a histocompatibility restriction exists in the capacity of spleen cells to activate primed PETLES and by the finding that antigen-pulsed spleen cells which have been washed and heat-treated before mixing with PETLES cause little or no stimulation in most experiments (Fig. 3). In 28 of the 38 experiments shown, stimulation by heat-killed spleen cells was 15% or less of the stimulation achieved with antigen-pulsed live cells. There were some experiments, however, which did show significant stimulation by heat-killed cells. In general, the data was disregarded from any experiment in which antigen-pulsed, heat-killed cells stimulated 15% or more of the response stimulated by live antigen-pulsed cells, because of the likelihood that soluble antigen might be carried over into such cultures.

*Antigen Presentation by Syngeneic, Semisyngeneic, or Allogeneic Spleen Cells.* Previous studies in the guinea pig (1, 2) have demonstrated the requirement for genetic identity at the MHC in order for peritoneal exudate cells to present antigen effectively to primed T lymphocytes. Experiments designed to test whether similar genetic restrictions applied to antigen presentation by murine spleen cells are shown in Table I. The experiments were set up in a crisscross fashion so that each presenting cell population was tested against both




FIG. 3. A frequency histogram of 38 experiments in which spleen cells were pulsed with 10-100  $\mu\text{g}/\text{ml}$  of  $\text{DNP}_6\text{OVA}$  and either added to syngeneic PETLES directly or heated to  $56^\circ\text{C}$  for 60 min, cooled to  $37^\circ\text{C}$ , and then added to the PETLES. The resulting proliferative responses are compared here by expressing the response to the heat-killed cells as a percentage of the response to the live cells.

syngeneic and allogeneic T lymphocytes. As shown in Table I, when PETLES from either B10 or B10.D2 mice primed to  $\text{DNP}_6\text{OVA}$  were stimulated in vitro with  $\text{DNP}_6\text{OVA}$  bound to spleen cells, use of syngeneic cells always resulted in greater antigen-specific proliferation ( $\Delta$  cpm antigen), than use of allogeneic cells. Thus, antigen-pulsed B10 spleen cells presented well to syngeneic B10 PETLES ( $\Delta$  cpm 30,000) but poorly to allogeneic B10.D2 PETLES ( $\Delta$  cpm 1,400) while antigen-pulsed B10.D2 spleen cells presented well to syngeneic B10.D2 PETLES ( $\Delta$  cpm 19,600) but poorly to allogeneic B10 PETLES ( $\Delta$  cpm 2,200). Semisyngeneic antigen-pulsed (B10  $\times$  B10.D2) $F_1$  spleen cells gave intermediate levels of stimulation for both types of responding T cells ( $\Delta$  cpm of 14,700 for B10 and 9,000 for B10.D2).

Stimulation of T-lymphocyte proliferation by antigen-pulsed allogeneic spleen cells was a strong function of the concentration of antigen used to pulse such cells. As shown in Fig. 4, stimulation of BALB/c PETLES by antigen-pulsed syngeneic spleen cells peaked when the spleen cells had been pulsed with 100

TABLE I  
*Antigen Presentation by Syngeneic, Semisyngeneic, or Allogeneic Spleen Cells*

| PETLES  | Spleen cells                 | DNP <sub>6</sub> OVA | Proliferative response on day 4 |                                |              |
|---------|------------------------------|----------------------|---------------------------------|--------------------------------|--------------|
|         |                              |                      | cpm ± SEM                       | Δ cpm (DNP <sub>6</sub> -OVA)* | Δ cpm (MLR)‡ |
| B10§    | B10                          | Nonpulsed            | 1,600 ± 300                     |                                | —            |
|         |                              | Pulsed               | 31,600 ± 100                    | 30,000                         |              |
|         | (B10 × B10.D2)F <sub>1</sub> | Nonpulsed            | 13,600 ± 1,200                  |                                | 12,000       |
|         |                              | Pulsed               | 28,300 ± 1,400                  | 14,700                         |              |
|         | B10.D2                       | Nonpulsed            | 21,500 ± 100                    |                                | 19,900       |
|         |                              | Pulsed               | 23,700 ± 4,400                  | 2,200                          |              |
| B10.D2§ | B10.D2                       | Nonpulsed            | 2,600 ± 800                     |                                | —            |
|         |                              | Pulsed               | 22,100 ± 2,300                  | 19,600                         |              |
|         | (B10 × B10.D2)F <sub>1</sub> | Nonpulsed            | 29,900 ± 1,000                  |                                | 27,300       |
|         |                              | Pulsed               | 38,900 ± 100                    | 9,000                          |              |
|         | B10                          | Nonpulsed            | 26,400 ± 2,300                  |                                | 23,800       |
|         |                              | Pulsed               | 27,800 ± 2,100                  | 1,400                          |              |

\* Δ cpm (DNP<sub>6</sub>OVA); cpm obtained with antigen-pulsed presenting cells minus cpm obtained with nonpulsed presenting cells.

‡ Δ cpm (MLR); cpm obtained with nonpulsed allogeneic presenting cells minus cpm obtained with nonpulsed syngeneic presenting cells.

§  $1.5 \times 10^6$  DNP<sub>6</sub>OVA-primed B10 and B10.D2 PETLES were cultured with  $1 \times 10^5$  DNP<sub>6</sub>OVA-pulsed or nonpulsed syngeneic, semisyngeneic, or allogeneic spleen cells for 4 days in microtiter plates.

μg/ml, whereas stimulation by antigen-pulsed allogeneic B10 spleen cells was still increasing at a pulsing concentration of 300 μg/ml. We suspect that the stimulation caused by allogeneic spleen cells pulsed with high concentrations of DNP<sub>6</sub>OVA reflects "carryover" of antigen, a phenomenon which would tend to obscure the genetic restrictions present in the system. In order to minimize this putative antigen carryover and to maximize the genetic differences, most experiments were carried out using 30-50 μg/ml of antigen for pulsing.

The differences between syngeneic, allogeneic, and semisyngeneic presenting cells appeared not to be caused by differences in the time-course of the proliferative responses they stimulated. As shown in Fig. 5, the responses for all three types of cells peaked after 4-5 days of in vitro incubation, similar to what has been reported for cultures containing free antigen present continuously (6). In addition, the hierarchy of presenting activity (syngeneic better than semisyngeneic better than allogeneic) was observed at all time points from day 3 to day 6.

One might explain the genetic restrictions seen in this system by postulating a suppressive effect in cultures with an ongoing mixed lymphocyte reaction (MLR). Because only the allogeneic and semiallogeneic cells generate a MLR (Table I), cultures containing them would be the ones that would be suppressed. The finding that antigen-presenting F<sub>1</sub> cells were superior to allogeneic cells




FIG. 4. Response of  $1 \times 10^5$  BALB/c PETLES to varying concentrations of DNP<sub>6</sub>OVA-pulsed BALB/c spleen cells (○—○) or DNP<sub>6</sub>OVA-pulsed B10 spleen cells (●—●). The results are expressed as  $\Delta$  cpm  $\pm$  SEM.




FIG. 5. Kinetics of antigen presentation by syngeneic (●—●), semisyngeneic (Δ—Δ), or allogeneic (○—○) spleen cells to  $1 \times 10^5$  B10 PETLES (A) or  $1 \times 10^5$  B10.D2 PETLES (B). The results are expressed as  $\Delta$  cpm  $\pm$  SEM.




FIG. 6. Syngeneic cells present antigen better than allogeneic cells in the presence of the same MLR.  $1 \times 10^6$  DNP<sub>6</sub>OVA-primed B10 PETLES were cultured with mixtures of equal numbers of DNP<sub>6</sub>OVA-pulsed B10 spleen cells [B10(+)] and nonpulsed B10.A spleen cells [B10.A(-)] (○—○), nonpulsed B10 spleen cells [B10(-)] and DNP<sub>6</sub>OVA-pulsed B10.A spleen cells [B10.A(+)] (●—●), or nonpulsed B10 spleen cells and nonpulsed B10.A spleen cells (△—△). Stimulation was assessed 5 days later by measuring the incorporation of a 16 h pulse of tritiated methyl-thymidine. The results are expressed as cpm.

could be accounted for by a less vigorous suppressive effect because they possess only 1/2 the number of MLR-stimulating determinants. Although this last point was not always supported by the data, experiments were set up to test directly the possibility that a suppressive effect of an ongoing MLR accounted for the genetic restrictions which we observed. These experiments involved mixing equal numbers of syngeneic and allogeneic spleen cells or equal numbers of syngeneic and semisyngeneic spleen cells and comparing the ability of these mixtures to stimulate PETLES when antigen was bound to one or the other type of spleen cell. Thus, in this form of experiment, an identical MLR existed for both types of antigen presentation. As shown in Figs. 6 and 7, the same patterns of stimulation were observed, namely syngeneic cells presented better than allogeneic cells (Fig. 6) or semisyngeneic cells (Fig. 7). Therefore, we conclude that MLR suppression cannot account for the genetic differences observed in the ability of antigen-pulsed spleen cells to activate PETLES from primed donors.

*An Mls Disparity between MHC Compatible Strains does not Inhibit Antigen Presentation.* The results presented in Figs. 6 and 7 demonstrate that a MLR induced by *H-2*-incompatible spleen cells does not suppress antigen presentation by spleen cells syngeneic to the responding PETLES population. The conclusion suggested by these results, that MLRs per se are not suppressive for antigen presentation, was supported by further experiments in which Mls-incompatible,






FIG. 7. Syngeneic spleen cells present antigen better than semisyngeneic spleen cells in the presence of the same MLR.  $1 \times 10^5$  DNP<sub>6</sub>OVA-primed B10 PETLES were cultured with mixtures of equal numbers of DNP<sub>6</sub>OVA-pulsed B10 spleen cells [B10(+)] and nonpulsed (B10  $\times$  B10.A)<sub>F<sub>1</sub></sub> spleen cells [F<sub>1</sub>(-)] (○—○), nonpulsed B10 spleen cells [B10(-)] and DNP<sub>6</sub>OVA-pulsed F<sub>1</sub> spleen cells [F<sub>1</sub>(+)] (●—●), or nonpulsed B10 spleen cells and nonpulsed F<sub>1</sub> spleen cells (△—△). Stimulation was assessed 5 days later by measuring the incorporation of a 16 h pulse of tritiated methyl-thymidine. The results are expressed as cpm.

MHC-identical spleen cells were used to present antigen (Table II). When BALB/c PETLES ( $H-2^d$ ,  $Mls^b$ ) primed to DNP<sub>6</sub>OVA were stimulated with DNP<sub>6</sub>OVA-pulsed DBA/2 spleen cells ( $H-2^d$ ,  $Mls^a$ ), the antigen-specific proliferative response achieved was almost as great as that obtained when syngeneic BALB/c spleen cells were used for antigen presentation, despite the large MLR. B10.D2 spleen cells ( $H-2^d$ ,  $Mls^b$ ), which are identical to BALB/c PETLES at both the  $H-2$  and  $Mls$  loci but different at many other loci, also presented DNP<sub>6</sub>OVA. In contrast, B10 spleen cells ( $H-2^b$ ,  $Mls^b$ ), which are compatible at the  $Mls$  locus but incompatible at the MHC, did not present DNP<sub>6</sub>OVA effectively. Note that the magnitudes of the two types of MLR were similar ( $\Delta$  cpm 19,900 for the MHC incompatibility and  $\Delta$  cpm 27,300 for the  $Mls$  incompatibility), yet antigen presentation occurred only in the case of MHC compatibility. These results and those of the previous section are interpreted as indicating that a MLR, in and of itself, does not suppress nor enhance the ability of spleen cells to present antigen to T lymphocytes. The failure of MHC allogeneic spleen cells to present antigen well is, therefore, interpreted as a requirement for genetic identity at a MHC locus in order for effective interaction between antigen-pulsed spleen cells and primed PETLES to occur.

*Genetic Mapping of the MHC Genes Required for Presentation of DNP<sub>6</sub>OVA.* In order to determine at which MHC loci common alleles were necessary for effective interactions between primed T lymphocytes and antigen-

TABLE II  
*Mls Incompatibility does not Affect Antigen Presentation*

| Spleen Cells* | <i>Mls</i> | <i>H-2</i> | DNP <sub>6</sub> OVA | cpm ± SEM      | Δ cpm (DNP <sub>6</sub> OVA)‡ | Δ cpm (MLR)§ |
|---------------|------------|------------|----------------------|----------------|-------------------------------|--------------|
| BALB/c        | <i>b</i>   | <i>d</i>   | Nonpulsed            | 1,300 ± 200    | 45,700                        | —            |
|               |            |            | Pulsed               | 47,000 ± 1,900 |                               |              |
| DBA/2         | <i>a</i>   | <i>d</i>   | Nonpulsed            | 28,600 ± 400   | 35,300                        | 27,300       |
|               |            |            | Pulsed               | 63,900 ± 4,400 |                               |              |
| B10.D2        | <i>b</i>   | <i>d</i>   | Nonpulsed            | 2,700 ± 700    | 56,800                        | 1,400        |
|               |            |            | Pulsed               | 59,500 ± 500   |                               |              |
| B10           | <i>b</i>   | <i>b</i>   | Nonpulsed            | 21,200 ± 1,800 | 3,900                         | 19,900       |
|               |            |            | Pulsed               | 25,100 ± 1,200 |                               |              |

\*  $1 \times 10^6$  DNP<sub>6</sub>OVA-primed BALB/c PETLES were cultured with  $1 \times 10^6$  DNP<sub>6</sub>OVA-pulsed or nonpulsed BALB/c, DBA/2, B10.D2, or B10 spleen cells for 5 days in microtiter plates.

‡ See footnote (\*) to Table I.

§ See footnote (‡) to Table I.

pulsed spleen cells to occur, the congenic resistant lines B10 and B10.A and their associated recombinant strains, B10.A(4R) (*kkbbbbbbb*)<sup>2</sup> and B10.A(5R) (*bbkkddddd*) were utilized as well as the recombinant strain A.TL (*skkkkkkkkd*). B10 and B10.A PETLES obtained from mice primed to DNP<sub>6</sub>OVA, were cultured with antigen-pulsed or nonpulsed spleen cells from B10, B10.A, B10.A(4R), B10.A(5R), or A.TL mice. As shown in Table III, DNP<sub>6</sub>OVA-pulsed B10 spleen cells stimulated the proliferation of B10 PETLES (Δ cpm 20,100), while these same spleen cells were ineffective in stimulating B10.A PETLES (Δ cpm 1,000). DNP<sub>6</sub>OVA-pulsed B10.A spleen cells gave opposite results; they stimulated B10.A PETLES (Δ cpm 11,100) more effectively than B10 PETLES (Δ cpm 3,100). The B10.A(5R) recombinant spleen cells behaved like B10 spleen cells in that they stimulated B10 PETLES (Δ cpm 12,400) more effectively than they stimulated B10.A PETLES (Δ cpm 1,600). As summarized in Table V, this result suggests that genetic identity at the *K* region or the *I-A* or *I-B* subregion is necessary to achieve effective interaction, but that identity at the subregions of *I* to the right of *I-B*, as well as at the *G*, *S*, and *D* regions, is not sufficient. B10.A(4R) spleen cells (Table III) behaved like B10.A spleen cells in that they stimulated B10.A PETLES (Δ cpm 14,000) more effectively than they stimulated B10 PETLES (Δ cpm 3,300). These results map the gene(s) controlling the interaction to the *K* region or *I-A* subregion (Table V). In order to test whether identity at the *K* region was necessary, A.TL spleen cells were used (Table III). These cells, when pulsed with DNP<sub>6</sub>OVA, stimulated B10.A PETLES well (Δ cpm 10,400) but B10 PETLES poorly (Δ cpm 3,000). Thus, compatibility at the *K* region is not essential for presentation of DNP<sub>6</sub>OVA.

The above results, taken collectively, suggest that effective presentation can be achieved when compatibility at the *I-A* subregion is present. However, the

<sup>2</sup> Letters in parentheses refer to the haplotype source of the *K*, *I-A*, *I-B*, *I-J*, *I-E*, *I-C*, *S*, *G*, and *D* alleles of the MHC.

TABLE III  
Responses of B10 and B10.A PETLES to DNP<sub>6</sub>OVA-Pulsed Spleen Cells from Congenic Resistant Lines and Recombinant Strains

| Spleen cells | PETLES        |                |               |                |                |               |
|--------------|---------------|----------------|---------------|----------------|----------------|---------------|
|              | B10           |                |               | B10.A          |                |               |
|              | Nonpulsed     | Pulsed         | $\Delta$ cpm* | Nonpulsed      | Pulsed         | $\Delta$ cpm* |
| B10          | 1,900 (500)‡  | 22,000 (200)   | 20,100        | 10,200 (700)   | 11,200 (700)   | 1,000         |
| B10.A        | 10,500 (400)  | 13,600 (400)   | 3,100         | 1,200 (500)    | 12,300 (1,800) | 11,100        |
| B10.A(5R)    | 6,300 (2,800) | 18,700 (1,300) | 12,400        | 21,100 (1,400) | 22,700 (4,000) | 1,600         |
| B10.A(4R)    | 13,400 (200)  | 16,700 (2,800) | 3,300         | 1,900 (100)    | 15,900 (2,300) | 14,000        |
| A.TL         | 8,800 (600)   | 11,800 (500)   | 3,000         | 13,100 (600)   | 23,500 (5,400) | 10,400        |

\*  $\Delta$  cpm, cpm obtained with DNP<sub>6</sub>OVA-pulsed spleen cells minus the cpm obtained with nonpulsed spleen cells.

‡ cpm; (1 SEM in parentheses).

TABLE IV  
Responses of A.TL and A.TH PETLES to DNP<sub>6</sub>OVA-Pulsed Spleen Cells from Congenic Resistant Lines and Recombinant Strains

| Spleen cells | PETLES         |                |               |                |                |               |
|--------------|----------------|----------------|---------------|----------------|----------------|---------------|
|              | A.TL           |                |               | A.TH           |                |               |
|              | Nonpulsed      | Pulsed         | $\Delta$ cpm* | Nonpulsed      | Pulsed         | $\Delta$ cpm* |
| A.TL         | 1,600 (200)‡   | 12,500 (1,400) | 10,900        | 16,700 (1,600) | 19,300 (1,800) | 2,600         |
| A.TH         | 14,100 (700)   | 14,100 (1,500) | 0             | 3,900 (1,000)  | 45,100 (600)   | 41,200        |
| SJL          | 14,900 (900)   | 17,400 (400)   | 2,500         | 12,200 (2,200) | 55,800 (1,600) | 43,600        |
| B10.A(4R)    | 10,900 (1,300) | 25,100 (100)   | 14,200        | 16,200 (200)   | 20,800 (1,100) | 4,600         |

\* cpm obtained with DNP<sub>6</sub>OVA-pulsed spleen cells minus the cpm obtained with nonpulsed spleen cells.

‡ cpm; (1 SEM in parentheses).

definitive proof of this hypothesis is presented in Table IV. A.TH (*sssssssd*) and A.TL (*skkkkkkd*) PETLES were obtained from mice primed to DNP<sub>6</sub>OVA. B10.A(4R) (*kkbbbbbb*) spleen cells pulsed with DNP<sub>6</sub>OVA presented as well to A.TL PETLES ( $\Delta$  cpm 14,200) as A.TL spleen cells ( $\Delta$  cpm 11,000), whereas SJL (*sssssss*) spleen cells ( $\Delta$  cpm 2,500) and A.TH spleen cells ( $\Delta$  cpm 0) were less effective. In contrast, the same SJL and A.TH spleen cells presented well to A.TH PETLES ( $\Delta$  cpm 43,600 for SJL and 41,200 for A.TH), demonstrating that they could function in antigen presentation. In this case it was the B10.A(4R) and A.TL spleen cells which were ineffective in presenting DNP<sub>6</sub>OVA to A.TH PETLES. These results demonstrate that compatibility at only *I-A* [B10.A(4R) and A.TL] is sufficient for effective presentation of DNP<sub>6</sub>OVA, whereas compatibility at only *K* (SJL and A.TL) is not (Table V).

### Discussion

The present studies have demonstrated the capacity of spleen cells from nonimmunized donors to bind and retain antigen in an immunogenic form and to effectively use this antigen to stimulate a proliferative response by primed T

TABLE V  
*The I-A Subregion Controls the Interaction between DNP<sub>o</sub>OVA-Pulsed Spleen Cells and Primed T Lymphocytes*

| Spleen Cells | B10 PETLES                  |                       | B10.A PETLES                |                          |
|--------------|-----------------------------|-----------------------|-----------------------------|--------------------------|
|              | <i>H-2</i> region identity* | % Syngeneic Response‡ | <i>H-2</i> region identity* | % of Syngeneic Response‡ |
| B10          | <i>K,A,B,J,E,C,S,G,D</i>    | <u>100</u>            | None                        | 9                        |
| B10.A        | None                        | 16                    | <i>K,A,B,J,E,C,S,G,D</i>    | <u>100</u>               |
| B10.A(5R)    | <i>K,A,B</i>                | <u>62</u>             | <i>J,E,C,S,G,D</i>          | 14                       |
| B10.A(4R)    | None                        | 16                    | <i>K,A</i>                  | <u>127</u>               |
| A.TL         | None                        | 15                    | <i>A,B,J,E,D</i>            | <u>94</u>                |
| A.TL PETLES  |                             | A.TH PETLES           |                             |                          |
| A.TL         | <i>K,A,B,J,E,C,S,G,D</i>    | <u>100</u>            | <i>K,D</i>                  | 6                        |
| A.TH         | <i>K,D</i>                  | 0                     | <i>K,A,B,J,E,C,S,G,D</i>    | <u>100</u>               |
| SJL          | <i>K</i>                    | 23                    | <i>K,A,B,J,E,C,S,G</i>      | <u>106</u>               |
| B10.A(4R)    | <i>A</i>                    | <u>130</u>            | None                        | 11                       |

\* Letters refer to regions or subregions of the MHC which are shared by the stimulating spleen cells and the responding PETLES. *A,B,J,E*, and *C* represent the subregions of *I*.

‡ ( $\Delta$  cpm of PETLES to DNP<sub>o</sub>OVA-pulsed allogeneic spleen cells/ $\Delta$  cpm of the same PETLES to DNP<sub>o</sub>OVA-pulsed syngeneic spleen cells)  $\times$  100. Underlined values indicate substantial responses.

lymphocytes in vitro. The nature of the cell type within the spleen cell population which is responsible for antigen presentation is now under active study. Based on results from guinea pig systems, we anticipate that this cell will prove to be an adherent, Ia-bearing macrophage.

In this paper we have demonstrated that there are certain genetic requirements for effective antigen presentation. Spleen cells histoincompatible at the MHC did not present antigen as well as syngeneic spleen cells. F<sub>1</sub> spleen cells were intermediate in presenting ability. Fine structure mapping indicated that identity of genes in the *I-A* subregion of the MHC was sufficient for effective presentation of the antigen, DNP<sub>o</sub>OVA. Identity at the *K* region only or at the *I-B* through *D* regions was not sufficient. However, we were unable to rule out the formal possibility that some combination of *K* and *I-B* through *G* genes might allow effective antigen presentation since the appropriate recombinants for testing this possibility do not exist. Thus, we can not conclude that identity of the *I-A* subregion is necessary, only that it is sufficient.

The histocompatibility requirements did not appear to be the result of suppressive or enhancing effects generated by MLRs for the following reasons. Mixtures of syngeneic and allogeneic or semisyngeneic spleen cells, in which all cultures developed the same MLR, still showed that syngeneic cells were superior in antigen-presenting ability. In addition, the presence of a MLR generated by a difference at the *Mls* locus did not affect antigen presentation if the cells were histocompatible at the MHC. Thus, some other mechanism must account for the observations.

At the present time, we favor the interpretation that primed T lymphocytes recognize antigen in association with gene products of the MHC expressed on

living cells. For cytotoxic cells nominally specific for viral (12), simple chemical (13), minor histocompatibility (14), or tumor-associated (15, 16) antigens, the association appears to be with *K* and *D* region gene products. For proliferating T cells in the guinea pig (1, 2) and delayed-typed hypersensitivity (DH) transferring cells in the mouse (3), the association would appear to be principally with *I* region products. In our system, we postulate that the PETLES population from immunized donors contain T cells which have been primed to DNP<sub>6</sub>OVA in association with syngeneic *I-A* region gene products. Stimulation with DNP<sub>6</sub>OVA on allogeneic spleen cells does not present the same combination of antigen and *I-A* subregion product and, therefore, would not be stimulatory. F<sub>1</sub> spleen cells do contain the correct allelic product and should be able to present DNP<sub>6</sub>OVA. The fact that they did not present antigen as well as syngeneic spleen cells we attribute to a gene dose effect (they possess only one copy of the syngeneic allele) although this remains to be proven.

This interpretation of the results leaves several unresolved questions. One is why the allogeneic cells should present at all since they do not possess the correct MHC allelic products. We believe this is the result of a phenomenon we call "antigen carryover." By this we mean that antigen-pulsed allogeneic spleen cells transfer or release antigen after being placed in culture. This antigen is accepted or bound by residual syngeneic antigen-presenting cells which in turn stimulate primed T lymphocytes. Our reasons for thinking this phenomenon is occurring are threefold. One is that heat-killed cells do release stimulatory antigen albeit only to a small degree (Fig. 3). Second, allogeneic stimulation occurs most often when the spleen cells are pulsed with high concentrations of antigen (Fig. 4) or when cell interactions are maximized by using larger numbers of PETLES in round bottom plates (R. H. Schwartz, unpublished observations). Third, recent observations on antigen-specific T-cell populations which have been selected *in vitro* and are devoid of antigen-presenting cells, indicate that, under such conditions, allogeneic spleen cells do not present at all (A. Yano, unpublished observations). On the other hand, it is possible that subpopulations of T lymphocytes exist which principally recognize free antigen; such cells might be triggered by antigen presented on allogeneic spleen cells. Indeed, Rosenwasser and Rosenthal (17) have recently studied the proliferative responses of lymph node T lymphocytes, depleted of syngeneic macrophages and reconstituted with syngeneic or allogeneic peritoneal exudate cells. In this system, no MHC restriction was observed for stimulation by purified protein derivative of tuberculin or DNP-OVA. It is also possible, based on the recent report of Gorczynski (18) that different subpopulations of antigen-presenting cells (macrophages) exist, some of which do and some of which do not show histocompatibility restriction in antigen presentation. Finally, it is possible that *I-A* gene products which are serologically distinct may "cross-react" to some extent in their antigen-presentation function.

The other unresolved problem is the failure of some workers to demonstrate histocompatibility requirements for helper T cell-macrophage interactions. Although the very early studies of Mitchison (19) using an adoptive transfer system, suggested that bovine serum albumin bound to allogeneic macrophages was ineffective in eliciting antibody formation, the subsequent detailed studies of Katz and Unanue (20) in an *in vitro* secondary anti-keyhole limpet hemocya-

nin antibody-forming system indicated that allogeneic macrophages and even fibroblasts, could present antigen effectively. This was despite the fact that these same workers could demonstrate allogeneic restrictions in T-B cell interactions (21, 22). More recently, however, Pierce et al. (5), Erb and Feldmann (4), and Kappler and Marrack (23) have been successful in demonstrating histocompatibility requirements for helper cell induction and antibody formation in vitro and in vivo. Although this recent work suggests that helper T cells show the same histocompatibility restrictions in their interactions with macrophages as do the proliferating T cells (1, 2) and the DH T cells (3), no adequate explanation for the lack of agreement has yet been offered. Even amongst those who agree that a histocompatibility restriction exists in the interaction of macrophages and helper T lymphocytes a consensus on the mechanism of the restrictions does not exist. Pierce et al. (5) have argued that the restriction occurs only in secondary antibody responses since allogeneic and syngeneic adherent cells work equally well in generating a primary plaque-forming cell (PFC) response to L-glutamic acid<sup>60</sup>-L-alanine<sup>30</sup>-L-tyrosine<sup>10</sup>, whereas syngeneic cells are markedly better than allogeneic cells in a secondary PFC response. The data of Cosenza and Leserman (24) on sheep erythrocyte primary PFC responses as well as the primary proliferation data of Thomas and Shevach (25, 26) support this concept. On the other hand, Erb and Feldmann (4) have isolated a macrophage factor which is necessary for primary helper cell induction in their system. This factor displays genetic restrictions despite the fact that it is generated by macrophages from unprimed donors. At the present time there is no obvious resolution of these conflicting results.

In conclusion, the results presented in this paper add to the growing body of evidence that suggests that most T cells recognize antigen in association with gene products of the MHC. The mechanisms by which this might occur have been discussed adequately in other publications from this laboratory (27, 28) as well as from other laboratories (3, 29, 30). Suffice it to say that the uniqueness of T-cell recognition and responsiveness is felt to be epitomized by the requirement for histocompatible cell interactions. That this might be the basis for *Ir* gene control of the immune response is currently being investigated.

### Summary

A method is described for stimulating proliferation in primed populations of murine T lymphocytes using antigen bound to mitomycin-C-treated spleen cells. This form of antigen presentation appears to be an active process because heat-killed spleen cells are ineffective, and because genetic similarity at the major histocompatibility complex (MHC) between the responder T cells and the presenting spleen cells is required for effective interactions. At all times examined, from day 3 to day 6 of the proliferative response, syngeneic spleen cells presented antigen better to peritoneal exudate T-lymphocyte-enriched cells (PETLES) than semisyngeneic F<sub>1</sub> spleen cells, which in turn could present antigen better than totally allogeneic spleen cells. Spleen cell mixing experiments demonstrated that these genetic restrictions were not the result of suppression by the ongoing mixed lymphocyte reactions (MLR) in the allogeneic and F<sub>1</sub> cases. Furthermore, incompatibility at the *Mls* locus generated a strong MLR but failed to prevent antigen presentation if the spleen cells and PETLES were *H-2*

compatible. Genetic mapping studies demonstrated that compatibility at only the *I-A* subregion of the MHC was sufficient for effective presentation of the antigen, dinitrophenylated ovalbumin. Compatibility at only the *K* region, or the *K* and *D* regions was not sufficient. These results support the concept that functional activation of primed, proliferating T lymphocytes requires the participation of gene products coded for by the *I* region of the MHC. This conclusion is consistent with a growing body of evidence which suggests that most T cells recognize antigen in association with MHC gene products.

Received for publication 23 May 1977.

### References

1. Rosenthal, A. S., and E. M. Shevach. 1973. Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. *J. Exp. Med.* 138:1194.
2. Shevach, E. M., and A. S. Rosenthal. 1973. Function of macrophages in antigen recognition by guinea pig T lymphocytes. II. Role of the macrophage in the regulation of genetic control of the immune response. *J. Exp. Med.* 138:1213.
3. Miller, J. F. A. P., M. A. Vadas, A. Whitelaw, and J. Gamble. 1975. H-2 gene complex restricts transfer of delayed-type hypersensitivity in mice. *Proc. Natl. Acad. Sci. U. S. A.* 72:5095.
4. Erb, P., and M. Feldmann. 1975. The role of macrophages in the generation of T-helper cells. II. The genetic control of the macrophage-T-cell interaction for helper cell induction with soluble antigens. *J. Exp. Med.* 142:460.
5. Pierce, C. W., J. A. Kapp, and B. Benacerraf. 1976. Regulation by the H-2 gene complex of macrophage-lymphoid cell interactions in secondary antibody responses in vitro. *J. Exp. Med.* 144:371.
6. Schwartz, R. H., L. Jackson, and W. E. Paul. 1976. T lymphocyte-enriched murine peritoneal exudate cells. I. A reliable assay for antigen-induced T lymphocyte proliferation. *J. Immunol.* 115:1330.
7. Schwartz, R. H., and W. E. Paul. 1976. T-lymphocyte-enriched murine peritoneal exudate cells. II. Genetic control of antigen-induced T-lymphocyte proliferation. *J. Exp. Med.* 143:529.
8. Schwartz, R. H., C. L. Horton, and W. E. Paul. 1977. T-lymphocyte-enriched murine peritoneal exudate cells. IV. Genetic control of cross-stimulation at the T-cell level. *J. Exp. Med.* 145:327.
9. Roos, D., and J. A. Loos. 1970. Changes in the carbohydrate metabolism of mitogenically stimulated human peripheral lymphocytes. I. Stimulation by phytohaemagglutinin. *Biochim. Biophys. Acta.* 222:565.
10. Rosenstreich, D. L., and A. S. Rosenthal. 1973. Peritoneal exudate lymphocyte. II. *In vitro* lymphocyte proliferation induced by brief exposure to antigen. *J. Immunol.* 110:934.
11. Waldron, J. A., Jr., R. G. Horn, and A. S. Rosenthal. 1974. Antigen-induced proliferation of guinea pig lymphocytes *in vitro*: functional aspects of antigen handling by macrophages. *J. Immunol.* 112:746.
12. Zinkernagel, R. M., and P. C. Doherty. 1975. H-2 compatibility requirement for T-cell-mediated lysis of targets infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded in H-2K or H-2D. *J. Exp. Med.* 141:1427.
13. Shearer, G. M., T. G. Rehn, and C. A. Garbarino. 1975. Cell-mediated lympholysis of trinitrophenyl-modified autologous lymphocytes. Effector cell specificity to modified

- cell surface components controlled by the *H-2K* and *H-2D* serological regions of the murine major histocompatibility complex. *J. Exp. Med.* 141:1348.
14. Bevan, M. J. 1975. The major histocompatibility complex determines susceptibility to cytotoxic T cells directed against minor histocompatibility antigens. *J. Exp. Med.* 142:1349.
  15. Germain, R. N., M. E. Dorf, and B. Benacerraf. 1975. Inhibition of T-lymphocyte-mediated tumor-specific lysis by alloantisera directed against the H-2 serological specificities of the tumor. *J. Exp. Med.* 142:1023.
  16. Schrader, J. W., and G. M. Edelman. 1976. Participation of the H-2 antigens of tumor cells in their lysis by syngeneic T cells. *J. Exp. Med.* 143:601.
  17. Rosenwasser, L. J., and A. S. Rosenthal. 1977. Roles of adherent cells in murine T cell antigen recognition. *In* *The Immune System: Genes and the Cells in Which They Function*. E. Sercarz, L. A. Herzenberg, and C. F. Fox, editors. Academic Press, Inc., New York. In press.
  18. Gorczyński, R. M. 1976. Control of the immune response: role of macrophages in regulation of antibody- and cell-mediated immune responses. *Scand. J. Immunol.* 5:1031.
  19. Mitchison, N. A. 1968. The immunogenic capacity of antigen taken up by peritoneal exudate cells. *Immunology.* 16:1.
  20. Katz, D. H., and E. R. Unanue. 1972. Critical role of determinant presentation in the induction of specific responses in immunocompetent lymphocytes. *J. Exp. Med.* 137:967.
  21. Katz, D. H., T. Hamaoka, and B. Benacerraf. 1973. Cell interaction between histoincompatible T and B lymphocytes. II. Failure of physiologic cooperative interactions between T and B lymphocytes from allogeneic donor strains in humoral response to hapten-protein conjugates. *J. Exp. Med.* 137:1405.
  22. Katz, D. H., M. Graves, M. E. Dorf, H. Dimuzio, and B. Benacerraf. 1975. Cell interactions between histoincompatible T and B lymphocytes. VII. Cooperative responses between lymphocytes are controlled by genes in the *I* region of the *H-2* complex. *J. Exp. Med.* 141:263.
  23. Kappler, J. W., and P. C. Marrack. 1976. Helper T cells recognize antigen and macrophage surface components simultaneously *Nature (Lond.)*. 262:797.
  24. Cosenza, H., and L. D. Leserman. 1972. Cell interactions in antibody formation *in vitro*. I. Role of the third cell in the *in vitro* response of spleen cells to erythrocyte antigen. *J. Immunol.* 108:418.
  25. Thomas, D. W., and E. M. Shevach. 1976. Nature of the antigenic complex recognized by T lymphocytes. I. Analysis with an *in vitro* primary response to soluble protein antigens. *J. Exp. Med.* 144:1263.
  26. Thomas, D. W., and E. M. Shevach. 1977. Nature of the antigenic complex recognized by T lymphocytes. III. Specific sensitization by antigens associated with allogeneic macrophages. *Proc. Natl. Acad. Sci. U. S. A.* 74:2104.
  27. Paul, W. E., and B. Benacerraf. 1977. Functional specificity of thymus-dependent lymphocytes. A relationship between the specificity of T lymphocytes and their functions is proposed. *Science (Wash. D. C.)*. 25:1293.
  28. Rosenthal, A. S., and E. M. Shevach. 1976. Macrophage-T lymphocyte interaction: the cellular basis for genetic control of antigen recognition. *In* *The Role of Products of the Histocompatibility Gene Complex in Immune Responses*. D. H. Katz, and B. Benacerraf, editors. Academic Press, Inc., New York. 335.
  29. Janeway, C. A., Jr., H. Binz, and H. Wigzell. 1976. Two different  $V_H$  gene products make up the T-cell receptors. *Scand. J. Immunol.* 5:993.
  30. Doherty, P. C., and R. M. Zinkernagel. 1975. A biological role for the major histocompatibility antigens. *Lancet.* 28:1406.